These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 29911578)

  • 1. Evaluation of the cost-effectiveness of buprenorphine in treatment of chronic pain using competing EQ-5D weights.
    Norrlid H; Dahm P; Tennvall GR
    Scand J Pain; 2015 Jan; 6(1):24-30. PubMed ID: 29911578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tramadol and the risk of fracture in an elderly female population: a cost utility assessment with comparison to transdermal buprenorphine.
    Hirst A; Knight C; Hirst M; Dunlop W; Akehurst R
    Eur J Health Econ; 2016 Mar; 17(2):217-27. PubMed ID: 25861916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and tolerability of transdermal buprenorphine patches: a multicenter, prospective, open-label study in Asian patients with moderate to severe chronic musculoskeletal pain.
    Yoon DH; Bin SI; Chan SK; Chung CK; In Y; Kim H; Lichauco JJ; Mok CC; Moon YW; Ng TK; Penserga EG; Shin DA; You D; Moon H
    BMC Musculoskelet Disord; 2017 Aug; 18(1):337. PubMed ID: 28778219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is buprenorphine transdermal patch equally safe and effective in younger and elderly patients with osteoarthritis-related pain? Results of an age-group controlled study.
    Karlsson J; Söderström A; Augustini BG; Berggren AC
    Curr Med Res Opin; 2014 Apr; 30(4):575-87. PubMed ID: 24320787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of low-dose transdermal buprenorphine patches (5, 10, and 20 microg/h) versus prolonged-release tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: a 12-week, randomized, open-label, controlled, parallel-group noninferiority study.
    Karlsson M; Berggren AC
    Clin Ther; 2009 Mar; 31(3):503-13. PubMed ID: 19393841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective, observational clinical study.
    Muriel C; Failde I; Micó JA; Neira M; Sánchez-Magro I
    Clin Ther; 2005 Apr; 27(4):451-62. PubMed ID: 15922818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
    Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
    Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The implications of using US-specific EQ-5D preference weights for cost-effectiveness evaluation.
    Noyes K; Dick AW; Holloway RG
    Med Decis Making; 2007; 27(3):327-34. PubMed ID: 17502449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic burden and dosing trends of buprenorphine buccal film and transdermal patch in chronic low back pain.
    Zah V; Stanicic F; Vukicevic D; Grbic D
    Pain Manag; 2024; 14(4):195-207. PubMed ID: 38939964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pain therapy in the elderly:7-day transdermal buprenorphine patch in clinical practice. Results of a non-interventional study].
    Wahle K; Krings D; Schwenke K
    MMW Fortschr Med; 2013 Mar; 155 Suppl 1():25-31. PubMed ID: 23678668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose 7-day transdermal buprenorphine in daily clinical practice - perceptions of elderly patients with moderate non-malignant chronic pain.
    Uberall MA; Müller-Schwefe GH
    Curr Med Res Opin; 2012 Oct; 28(10):1585-95. PubMed ID: 22978772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of total disc replacement versus multidisciplinary rehabilitation in patients with chronic low back pain: a Norwegian multicenter RCT.
    Johnsen LG; Hellum C; Storheim K; Nygaard ØP; Brox JI; Rossvoll I; Rø M; Andresen H; Lydersen S; Grundnes O; Pedersen M; Leivseth G; Olafsson G; Borgström F; Fritzell P;
    Spine (Phila Pa 1976); 2014 Jan; 39(1):23-32. PubMed ID: 24150435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of ferric carboxymaltose in iron-deficient patients with chronic heart failure in Sweden.
    Hofmarcher T; Borg S
    J Med Econ; 2015; 18(7):492-501. PubMed ID: 25766863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Socioeconomic value of intervention for chronic pain.
    Takura T; Shibata M; Inoue S; Matsuda Y; Uematsu H; Yamada K; Ushida T
    J Anesth; 2016 Aug; 30(4):553-61. PubMed ID: 27002511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Long-term treatment of chronic pain with low-dose 7-day buprenorphine transdermal patch. Observational data from elderly patients of pain relief and quality of life].
    Uberall MA; Müller-Schwefe GH
    MMW Fortschr Med; 2013 Oct; 155 Suppl 3():87-96. PubMed ID: 24930319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of the pharmacological management of chronic low back pain with four leading drugs.
    Kaito T; Matsuyama Y; Yamashita T; Kawakami M; Takahashi K; Yoshida M; Imagama S; Ohtori S; Taguchi T; Haro H; Taneichi H; Yamazaki M; Inoue G; Nishida K; Yamada H; Kabata D; Shintani A; Iwasaki M; Ito M; Miyakoshi N; Murakami H; Yonenobu K; Takura T; Mochida J;
    J Orthop Sci; 2019 Sep; 24(5):805-811. PubMed ID: 31230950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching from high doses of pure μ-opioid agonists to transdermal buprenorphine in patients with cancer: a feasibility study.
    Lundorff L; Sjøgren P; Hansen OB; Jonsson T; Nielsen PR; Christrup L
    J Opioid Manag; 2013; 9(4):255-62. PubMed ID: 24353018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of lumbar fusion and nonsurgical treatment for chronic low back pain in the Swedish Lumbar Spine Study: a multicenter, randomized, controlled trial from the Swedish Lumbar Spine Study Group.
    Fritzell P; Hägg O; Jonsson D; Nordwall A;
    Spine (Phila Pa 1976); 2004 Feb; 29(4):421-34; discussion Z3. PubMed ID: 15094539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of balloon kyphoplasty versus standard medical treatment in patients with osteoporotic vertebral compression fracture: a Swedish multicenter randomized controlled trial with 2-year follow-up.
    Fritzell P; Ohlin A; Borgström F
    Spine (Phila Pa 1976); 2011 Dec; 36(26):2243-51. PubMed ID: 21912321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.